Purchase this article with an account.
P. Grenga, E.M. Vingolo, S. Cavarretta, A. Labate, E. Perrotta; Valuation of Retinal Thickness Changes Measured by OCT in Diabetic Cystoid Macular Oedema . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1429.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To study the safety and the efficacy of intravitreal Triamcinolone acetonide in patients with diabetic cystoid macular oedema. Methods: 12 eyes affected by diabetic cystoid macular oedema received 8 mg in 0.2 ml preservative free intravitreal triamcinolone injection delivered through the pars plana using a 27 or 30 gauge needle. We reviewed the retinal thickness before and after the injection by OCT retinal thickness map analyser . All the patients were submitted to a complete ophthalmological examination (Visual Acuity, biomicroscopy, IOP measurement, ophthalmoscopic fundus examination, fluorangiography). We made OCT examination before the injection 15 days, and 1 month after. All the patients were informed. Results: In each patients we observed a significant improvement both functionally and anatomically. The foveal thickness in OCT was reduced significantly from preoperative 692+70 microns to 313,6+54 microns after fifteen days, with a mean reduction of 378+124 microns. After 1 month from the baseline we reviewed a mean foveal thickness of 331.6+52.5 microns, with a mean increasing from the postoperative of 18+53 microns. Mean improvement in Visual Acuity measured 1.5 Snellen lines at 1 month. The effect persisted for three months. The side–effect described in the literature were not observed, the IOP increasing in the postoperative period was not significant. Conclusions: Intravitreal triamcinolone acetonide may decrease retinal thickness in patients suffering from diabetic cystoid macular oedema and improve visual acuity. It’s an important way to care that patients not responding to the photocoagulation therapy.
This PDF is available to Subscribers Only